Extranodal natural killer/T-cell lymphoma with long-term survival and repeated relapses: Does it indicate the presence of indolent subtype?

Seok Jin Kim, Yong Park, Byung Soo Kim, Insun Kim, Young Hye Ko, Won Seog Kim

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background: Extranodal natural killer (NK)/T-cell lymphoma is a subtype of lymphoma that is derived from NK cells. It is considered as an aggressive form of non-Hodgkin's lymphoma because of frequent relapses and resistance to treatment. Relapsed NK/T-cell lymphoma often follows a fulminant course that is refractory to conventional chemotherapy treatment. Methods: Several patients with extranodal NK/T-cell lymphoma showed long-term survival in spite of frequent relapses. Thus, the medical records of patients diagnosed with extranodal NK/T-cell lymphoma from 1995 to 2007 were reviewed and assessed. Results: Of the 140 cases reviewed, 6 were selected (4.29%). Each of these patients had a minimum of 3 relapses or disease progression during the follow-up period, and their median overall survival was 66 months (range, 42-89 months). They were grouped according to the atypical clinical behavior observed: (1) repeated relapses or progression (≥3 times) during follow-up; and (2) long-term survival of more than 40 months, as the longest overall survival median was previously considered at approximately 40 months. The clinicopathological and laboratory characteristics of these patients were similar to those of other extranodal NK/T-cell lymphoma patients. However, 5 of the studied cases involved relatively lower expression of the proliferation-related antigen Ki-67 (< 40-50%), indicating less proliferative activity. Clinically, they showed delayed relapse for at least 20 months after the initial complete remission. Conclusion: Our observations suggest that the clinical behavior of some extranodal NK/T-cell lymphoma patients differs from the typical clinical course.

Original languageEnglish
Pages (from-to)202-206
Number of pages5
JournalKorean Journal of Hematology
Volume47
Issue number3
DOIs
Publication statusPublished - 2012 Dec 1

Fingerprint

Natural Killer T-Cells
T-Cell Lymphoma
Recurrence
Survival
Ki-67 Antigen
Natural Killer Cells
Non-Hodgkin's Lymphoma
Medical Records
Disease Progression
Lymphoma
Drug Therapy
Therapeutics

Keywords

  • Extranodal NK/T-cell lymphoma
  • Indolent
  • Relapse
  • Survival

ASJC Scopus subject areas

  • Hematology

Cite this

Extranodal natural killer/T-cell lymphoma with long-term survival and repeated relapses : Does it indicate the presence of indolent subtype? / Kim, Seok Jin; Park, Yong; Kim, Byung Soo; Kim, Insun; Ko, Young Hye; Kim, Won Seog.

In: Korean Journal of Hematology, Vol. 47, No. 3, 01.12.2012, p. 202-206.

Research output: Contribution to journalArticle

@article{2da0185f799d4885852de9f88e128176,
title = "Extranodal natural killer/T-cell lymphoma with long-term survival and repeated relapses: Does it indicate the presence of indolent subtype?",
abstract = "Background: Extranodal natural killer (NK)/T-cell lymphoma is a subtype of lymphoma that is derived from NK cells. It is considered as an aggressive form of non-Hodgkin's lymphoma because of frequent relapses and resistance to treatment. Relapsed NK/T-cell lymphoma often follows a fulminant course that is refractory to conventional chemotherapy treatment. Methods: Several patients with extranodal NK/T-cell lymphoma showed long-term survival in spite of frequent relapses. Thus, the medical records of patients diagnosed with extranodal NK/T-cell lymphoma from 1995 to 2007 were reviewed and assessed. Results: Of the 140 cases reviewed, 6 were selected (4.29{\%}). Each of these patients had a minimum of 3 relapses or disease progression during the follow-up period, and their median overall survival was 66 months (range, 42-89 months). They were grouped according to the atypical clinical behavior observed: (1) repeated relapses or progression (≥3 times) during follow-up; and (2) long-term survival of more than 40 months, as the longest overall survival median was previously considered at approximately 40 months. The clinicopathological and laboratory characteristics of these patients were similar to those of other extranodal NK/T-cell lymphoma patients. However, 5 of the studied cases involved relatively lower expression of the proliferation-related antigen Ki-67 (< 40-50{\%}), indicating less proliferative activity. Clinically, they showed delayed relapse for at least 20 months after the initial complete remission. Conclusion: Our observations suggest that the clinical behavior of some extranodal NK/T-cell lymphoma patients differs from the typical clinical course.",
keywords = "Extranodal NK/T-cell lymphoma, Indolent, Relapse, Survival",
author = "Kim, {Seok Jin} and Yong Park and Kim, {Byung Soo} and Insun Kim and Ko, {Young Hye} and Kim, {Won Seog}",
year = "2012",
month = "12",
day = "1",
doi = "10.5045/kjh.2012.47.3.202",
language = "English",
volume = "47",
pages = "202--206",
journal = "Blood Research",
issn = "2287-979X",
publisher = "Korean Society of Hematology",
number = "3",

}

TY - JOUR

T1 - Extranodal natural killer/T-cell lymphoma with long-term survival and repeated relapses

T2 - Does it indicate the presence of indolent subtype?

AU - Kim, Seok Jin

AU - Park, Yong

AU - Kim, Byung Soo

AU - Kim, Insun

AU - Ko, Young Hye

AU - Kim, Won Seog

PY - 2012/12/1

Y1 - 2012/12/1

N2 - Background: Extranodal natural killer (NK)/T-cell lymphoma is a subtype of lymphoma that is derived from NK cells. It is considered as an aggressive form of non-Hodgkin's lymphoma because of frequent relapses and resistance to treatment. Relapsed NK/T-cell lymphoma often follows a fulminant course that is refractory to conventional chemotherapy treatment. Methods: Several patients with extranodal NK/T-cell lymphoma showed long-term survival in spite of frequent relapses. Thus, the medical records of patients diagnosed with extranodal NK/T-cell lymphoma from 1995 to 2007 were reviewed and assessed. Results: Of the 140 cases reviewed, 6 were selected (4.29%). Each of these patients had a minimum of 3 relapses or disease progression during the follow-up period, and their median overall survival was 66 months (range, 42-89 months). They were grouped according to the atypical clinical behavior observed: (1) repeated relapses or progression (≥3 times) during follow-up; and (2) long-term survival of more than 40 months, as the longest overall survival median was previously considered at approximately 40 months. The clinicopathological and laboratory characteristics of these patients were similar to those of other extranodal NK/T-cell lymphoma patients. However, 5 of the studied cases involved relatively lower expression of the proliferation-related antigen Ki-67 (< 40-50%), indicating less proliferative activity. Clinically, they showed delayed relapse for at least 20 months after the initial complete remission. Conclusion: Our observations suggest that the clinical behavior of some extranodal NK/T-cell lymphoma patients differs from the typical clinical course.

AB - Background: Extranodal natural killer (NK)/T-cell lymphoma is a subtype of lymphoma that is derived from NK cells. It is considered as an aggressive form of non-Hodgkin's lymphoma because of frequent relapses and resistance to treatment. Relapsed NK/T-cell lymphoma often follows a fulminant course that is refractory to conventional chemotherapy treatment. Methods: Several patients with extranodal NK/T-cell lymphoma showed long-term survival in spite of frequent relapses. Thus, the medical records of patients diagnosed with extranodal NK/T-cell lymphoma from 1995 to 2007 were reviewed and assessed. Results: Of the 140 cases reviewed, 6 were selected (4.29%). Each of these patients had a minimum of 3 relapses or disease progression during the follow-up period, and their median overall survival was 66 months (range, 42-89 months). They were grouped according to the atypical clinical behavior observed: (1) repeated relapses or progression (≥3 times) during follow-up; and (2) long-term survival of more than 40 months, as the longest overall survival median was previously considered at approximately 40 months. The clinicopathological and laboratory characteristics of these patients were similar to those of other extranodal NK/T-cell lymphoma patients. However, 5 of the studied cases involved relatively lower expression of the proliferation-related antigen Ki-67 (< 40-50%), indicating less proliferative activity. Clinically, they showed delayed relapse for at least 20 months after the initial complete remission. Conclusion: Our observations suggest that the clinical behavior of some extranodal NK/T-cell lymphoma patients differs from the typical clinical course.

KW - Extranodal NK/T-cell lymphoma

KW - Indolent

KW - Relapse

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=84874071964&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84874071964&partnerID=8YFLogxK

U2 - 10.5045/kjh.2012.47.3.202

DO - 10.5045/kjh.2012.47.3.202

M3 - Article

C2 - 23071475

AN - SCOPUS:84874071964

VL - 47

SP - 202

EP - 206

JO - Blood Research

JF - Blood Research

SN - 2287-979X

IS - 3

ER -